Compare Shopify Inc. (SHOP) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shopify Inc. vs BIO-TECHNE Corp — how do they compare? Shopify Inc. trades at $127 (market cap $172.54B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Shopify Inc. is far larger — about 15.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Shopify Inc. pays none. Which is the better fit depends on your goals.
| SHOP | TECH | |
|---|---|---|
Market Cap | $172.54B | $11.34B |
Sector | Technology | Health |
52-Week High | $179.01 | $72.48 |
52-Week Low | $95.40 | $43.31 |
Enterprise Value | $167.77B | $11.36B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHOP trades at $134.1, down 7.57% in the past 24 hours, reflecting recent market pressure. The stock is near its 52-week low of $130.00, with technical indicators showing a bearish trend. Fundamentally, revenue grew to $11.56B in 2025, but the P/E ratio of 90.61 suggests a premium valuation. Recent news highlights AI initiatives and competitive comparisons, while earnings show mixed quarterly results with a miss in Q4 2025 but beats in Q1 and Q2 2026.
Outlook: Strong revenue growth and expanding gross merchandise volume support long-term potential, but high valuation and recent price decline pose near-term risks. Analyst consensus is bullish with a $167.50 price target, though competitive pressures and market volatility require careful monitoring for investors.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
